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Research on tuberous sclerosis complex (TSC) to date has focused mainly on the
physical manifestations of the disease. In contrast, the psychosocial impact of TSC has
received far less attention. The aim of this study was therefore to examine the impact
of TSC on health, quality of life (QoL), and psychosocial well-being of individuals with
TSC and their families. Questionnaires with disease-specific questions on burden of
illness (BOI) and validated QoL questionnaires were used. After completion of additional
informed consent, we included 143 individuals who participated in the TOSCA (TuberOus
SClerosis registry to increase disease Awareness) study. Our results highlighted the
substantial burden of TSC on the personal lives of individuals with TSC and their
families. Nearly half of the patients experienced negative progress in their education
or career due to TSC (42.1%), as well as many of their caregivers (17.6% employed;
58.8% unemployed). Most caregivers (76.5%) indicated that TSC affected family life, and
social and working relationships. Further, well-coordinated care was lacking: a smooth
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transition from pediatric to adult care was mentioned by only 36.8% of adult patients,
and financial, social, and psychological support in 21.1, 0, and 7.9%, respectively. In
addition, the moderate rates of pain/discomfort (35%) and anxiety/depression (43.4%)
reported across all ages and levels of disease demonstrate the high BOI and low QoL in
this vulnerable population.
Keywords: tuberous sclerosis complex, quality of life, burden of illness, epilepsy, TOSCA
INTRODUCTION
Tuberous sclerosis complex (TSC) is a multi-system genetic
disorder with a global incidence of 1 per 6,000–10,000 live births.
Over a million people are estimated to be affected worldwide
(1). It is characterised by growth of benign tumours in various
organs throughout the body, including the brain, kidney, lungs,
and skin (2). It is also associated with behavioural, psychiatric,
intellectual, academic, neuropsychological, and psychosocial
difficulties, grouped under the umbrella term TAND (TSC-
Associated Neuropsychiatric Disorders) (3, 4). The clinical
presentation of TSC manifestations is complex (5–8). Its natural
course varies between individuals, with symptoms occurring at
variable ages and severity ranging from very mild to severe,
which may even lead to death. Furthermore, individuals with
TSC are expected to have lifelong follow-up care to ensure
the early detection of potentially life-threatening complications.
The diverse clinical presentation represents significant disease,
healthcare, and treatment burden (9).
To date, the majority of TSC research has concentrated on
the pathophysiology, epidemiology, diagnosis, and treatment of
the condition (10). Relatively little has been done to evaluate the
impact of TSC on the quality of life (QoL) and social well-being of
individuals with TSC and their families. A number of researchers
have focused on the burden of specific aspects of TSC, such
as epilepsy, subependymal giant cell astrocytoma (SEGA), facial
angiofibroma, and renal angiomyolipoma (8, 9, 11–14). Others
have evaluated the impact of specific treatments on QoL such as
following epilepsy surgery (15), or have studied specific groups
such as the impact on adult caregivers (10, 16). A retrospective
study that evaluated parents of 99 children with TSC showed
that about 50% reported clinically significant parental stress. The
stress was related to the presence of current seizures, a history of
psychiatric diagnosis, intellectual disability, and/or behavioural
problems in the children (17). A web-based United Kingdom
(UK) survey of individuals with TSC and their caregivers showed
significantly lower health state utility values (HSUVs) compared
with the general population reference value for the UK value set
of the three-level version of the EuroQol-5D (EQ-5D-3L). This
indicates substantial impairment in individuals with TSC (18).
Zöllner et al. performed a systematic review on the burden of
illness (BOI) in TSC and included 33 articles published up to
October 2019, only 14 of which addressed QoL (19). We sought
to assess the impact of TSC on the lives of individuals or their
caregivers in terms of BOI and QoL, using a combination of
ancillary disease-specific questions on BOI and validated QoL
questionnaires in seven European countries.
METHODS
TOSCA, a natural history registry in TSC, was conducted in 170
sites across 31 countries worldwide. A detailed description of
the methods of the TOSCA study has been provided previously
(20). The registry consists of a “core” section and six “petals”
or “research projects”. Here, we present findings from one of
the research projects focusing on BOI and QoL in individuals
with TSC.
Participants
Selection of countries participating in this research project was
based on the availability of the validated QoL questionnaires
in the primary language used in that country. Based on this
criterion, TSC individuals of any age from seven European
countries were eligible for this specific research project, after
signing an additional consent form.
Measuring Burden of Illness
All enrolled individuals were asked to complete a set of
ancillary questions addressing social care needs (circumstances of
living arrangements, financial, social, and psychological support,
and information sources), healthcare needs (health insurance,
medical care and level of satisfaction, genetic testing, and
genetic counselling), impact on education and employment,
impact on family, and transition from paediatric to adult
care (Supplementary Material). These ancillary questions were
developed by patient representatives, who were part of the
TOSCA Working Committee in collaboration with the TSC
patient associations. Draft questionnaires were reviewed by two
caregivers for clarity and comprehensiveness. When individuals
were unable to complete the questionnaires by themselves,
caregivers were asked to complete the proxy version of the
questionnaires (caregiver report).
Measuring Quality of Life
For evaluating QoL, validated questionnaires in local languages
were administered to individuals with TSC/caregivers
who participated in this research project. These included
the following: (1) EuroQol-5D (EQ-5D), a self-complete
questionnaire for adults (age, ≥18 years); the EQ-5D proxy
version 1 was completed by the caregiver for children or
adolescents for adults who were unable to complete the report
by themselves; (2) QoL in Epilepsy Inventory-31-Problems
(QOLIE-31)-P for adults (age, ≥18 years) with epilepsy,
completed by the individuals themselves; (3) QoL in Childhood
Epilepsy (QOLCE) for children <10 years old with epilepsy
(completed by caregivers); (4) QoL in Epilepsy Inventory for
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Adolescents-48 (QOLIE-AD-48) for children aged 11–17 years
with epilepsy, completed by the subjects themselves.
Data Analyses
Data on QoL and BOI were recorded once (i.e., no follow
up requested) before the data cut-off date (10 August, 2017).
A copy of the collected paper questionnaires was sent from
each clinical site to the clinical research organization (CRO)
for data entry in the TOSCA study. Data were then extracted
and analysed by the CRO. Responses to the BOI questions
and QOL scales were summarised by descriptive statistics
(number of responders, mean, standard deviation, median,
range, frequency), considering age-based subgroup as children
(<11 years), adolescents (age 11 to <18 years) and adults (age
≥18 years).
Individuals with TSC or their caregivers, rated their level
of impairment across five dimensions (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression). Each
dimension has three levels: no problems, some problem and
confined to bed. The mean thermometer score for EQ-5D and
mean health state score for QOLIE-31-P questionnaire were
recorded on a scale from 0 to 100, with 0 being the worst
health state imaginable and 100 the best. Furthermore, each
patient rated the importance of the seven QOLIE 31-P sub scales
TABLE 1 | Demographic characteristics.
Overall (N = 143)
Sex #
Male 54 (37.8)
Female 88 (61.5)
Age at consent (years)
n 142
Mean (SD) 19.8 (15.24)
Median (range) 14 (3–72)
Duration of TSC (years)
n 141
Mean (SD) 13.5 (9.44)
Median (range) 11.2 (1.6–43.5)
Country
Belgium 24 (16.8)
France 30 (21.0)
Germany 11 (7.7)
Italy 58 (40.6)
Spain 11 (7.7)
Sweden 6 (4.2)
UK 3 (2.1)
Individuals with epilepsy
n(%) 67 (46.9)
Duration of epilepsy (years) at start of research project
n 66
Mean (SD) 16.6 (12.53)
Median (range) 12.8 (2.7–55.4)
#Information on sex was not available for 1 patient. Values are expressed as n (%) unless
otherwise stated.
(energy, mood, daily activities, cognition, medication effects,
seizure worry, and overall quality of life) from one to seven, with
one being the most important topic and seven the least important
one. The sub-scale scores of QOLIE-31-P questionnaire were the
means of the converted item scores multiplied by the distress
score. The total QOLIE-31-P score was calculated by dividing
the sum of the sub scales by the sum of the distress scores
TABLE 2 | Social care needs: self- and caregiver-reported outcomes.
Self-reported
individuals with TSC
Individuals with TSC
reported by
caregivers
Adolescents
N = 17
Adults
N = 38
Children/
Adolescents
N = 71
Adults
N = 17
Circumstances of living arrangements
Lives alone NA 5 (13.2) NA 1 (5.9)
Lives with
spouse/partner
NA 21 (55.3) NA 2 (11.8)
Lives with other family NA 10 (26.3) NA 13 (76.5)
Information missing NA 2 (5.3) NA 1 (5.9)
Help with daily activities needed
Yes NA 3 (7.9) NA 8 (47.1)
No NA 35 (92.1) NA 9 (52.9)
Assistance at home
Nurse 0 0 1 (1.4) 1 (5.9)
Daily assistance by
professional carer (paid)
1 (5.9) 0 5 (7.0) 1 (5.9)
Caregiver assistance from
friend/family/relative (not
paid)
0 5 (13.2) 16 (22.5) 7 (41.2)
Individuals felt that
assistance and support at
home was not sufficient
5 (29.4) 16 (42.1) 31 (43.7) 6 (35.3)
Financial, social, and psychological support
Disability allowance 6 (35.3) 8 (21.1) 39 (54.9) 13 (76.5)
Caregiver allowance 1 (5.9) 0 9 (12.7) 0
Social worker assistance 1 (5.9) 0 6 (8.5) 1 (5.9)
Social services support 1 (5.9) 0 3 (4.2) 2 (11.8)
Psychological counselling 2 (11.8) 3 (7.9) 10 (14.1) 0
Used sources for information about rights and benefits
Physician 7 (41.2) 25 (65.8) 46 (64.8) 9 (52.9)
Internet/Websites 9 (52.9) 14 (36.8) 49 (69.0) 7 (41.2)
Patient group 2 (11.8) 5 (13.2) 20 (28.2) 6 (35.3)
Social worker 1 (5.9) 1 (2.6) 21 (29.6) 3 (17.6)
Local government 1 (5.9) 4 (10.5) 6 (8.5) 2 (11.8)
Nurse 0 2 (5.3) 3 (4.2) 3 (17.6)
Most useful source
Physician 9 (52.9) 25 (65.8) 34 (47.9) 8 (47.1)
Internet/Websites 4 (23.5) 4 (10.5) 19 (26.8) 3 (17.6)
Patient group 2 (11.8) 2 (5.3) 12 (16.9) 4 (23.5)
Social worker 1 (5.9) 0 13 (18.3) 3 (17.6)
Local government 1 (5.9) 2 (5.3) 3 (4.2) 0
Nurse 0 0 1 (1.4) 0
NA not applicable. Values are expressed as n (%).
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multiplied by 100. If more than half the items in a sub-scale
had not answered, the sub-scale was not included in the total
score. For each sub scale of QOLCE, the answer for each item
was converted to a 0 to 100 point score, where high scores reflect
the highest level of functioning.
RESULTS
Hundred fouty three individuals (88 children and adolescents,
and 55 adults) from seven European countries were enrolled in
this research project as part of the TOSCA study (Table 1). The
mean time since initial diagnosis of TSC was 13.5 years (median,
11.2 years; range, 1.6–43.5). Of the 143 individuals enrolled, 67
(28 adults) had epilepsy (46.9%). The mean duration of epilepsy
was 16.6 years (median, 12.8 years; range, 2.7–55.4).
Burden of Illness: Self-Reported Outcomes
17 adolescents (19.3%; aged between 11 and <18 years) and 38
adults (69.1%) completed the questionnaire independently. Of
these, one (5.9%) adolescent and five adults (13.2%) needed extra
assistance at home. In most cases, assistance was provided by
unpaid caregivers (a family member or friend). 29.4% adolescents
and 42.1% of adults felt that assistance and support at home
was not sufficient (Table 2). Financial, social, and psychological
support was received by 8 (21.1%), 0 (0%), and 3 (7.9%) of adult
respondent, respectively.
Nine adolescents (52.9%) and 16 adults (42.1%) had access
to public and/or private insurance (Table 3). Although none of
the individuals reported that they had to pay extra for private
insurance due to TSC, two adults (5.3%) reported that health
or any kind of insurance was denied due to TSC. TSC was
managed by TSC specialists in 12 adolescents (70.6%) and 28
adults (73.7%). Twenty-nine adults (76.3%) reported that they
had access to a TSC clinic when required, while no access to TSC
clinics were reported by six adults (15.8%). TSC was managed
by more than three physicians in 15 adults (39.5%). Smooth
transition from paediatric to adult care was reported by only 14
adults (36.8%). Nearly one fifth of patients were dissatisfied with
various aspects of their medical care and nearly 50%were not able
to report if their care followed clinical guidelines (Figure 1).
TSC was reported to have impacted the career/education
progress in three adolescents (17.6%; Table 4). Fourteen
adolescents (82.4%) were in mainstream education. Six
adolescents (35.3%) received additional support in class; no
adolescents were home-schooled. Of the 38 adults, 20 (52.6%)
were employed and seven were not able to work (4 due to TSC; 3
due to other reasons). Sixteen adults (42.1%) expressed that TSC
had affected their career or education in different ways: impact
on career progression/promotions (25%), choice of career (25%),
loss of employment (31.3%), part-time rather than full-time
work (31.3%), or attainment of education level (37.5%).
Burden of Illness: Caregiver-Reported
Outcomes
Parents/Caregivers completed the questionnaires for
71 children and adolescents (80.7%; 38 girls and 32
boys) and 17 adults (30.9%; 11 female and 6 male)
TABLE 3 | Health care needs: self- and caregiver-reported outcomes.
Self-reported
individuals with TSC
Caregivers-reported
individuals with TSC
Adolescents
N = 17
Adults
N = 38
Children/
adolescents
N = 71
Adults
N = 17
Individuals with health insurance
Private insurance 2 (11.8) 7 (18.4) 31 (43.7) 6 (35.3)
Public insurance 6 (35.3) 14 (36.8) 37 (52.1) 4 (23.5)
No insurance 7 (41.2) 15 (39.5) 11 (15.5) 8 (47.1)
Individuals thought to
have paid extra for
private insurance due
to TSC condition
0 0 1 (1.4) 0
Public insurance was
denied due to TSC
0 2 (5.3) 9 (12.7) 1 (5.9)
Genetic testing
Patient had genetic
testing for TSC
13 (76.5) 31 (81.6) 57 (80.3) 16 (94.1)
Patient was offered
genetic testing but did
not do it
1 (5.9) 1 (2.6) 3 (4.2) 0
Patient had not been
offered genetic testing
for TSC
0 3 (7.9) 7 (9.9) 1 (5.9)
Genetic counselling
Patient had genetic
counselling
9 (52.9) 26 (68.4) 43 (60.6) 10 (58.8)
Patient was offered
genetic counselling
but decided not to
have it
0 0 3 (4.2) 0
Patient had not been
offered genetic
counselling for TSC
4 (23.5) 6 (15.8) 19 (26.8) 4 (23.5)
Number of doctors managing TSC
1 8 (47.1) 12 (31.6) 17 (23.9) 6 (35.3)
2 3 (17.6) 5 (13.2) 11 (15.5) 1 (5.9)
3 0 3 (7.9) 11 (15.5) 2 (11.8)
>3 6 (35.3) 15 (39.5) 31 (43.7) 7 (41.2)
Data not provided 0 3 (7.9) 1 (1.4) 1 (5.9)
TSC is managed by*
General
practitioner/family
doctor
1 (5.9) 9 (23.7) 17 (23.9) 6 (35.3)
TSC specialist 12 (70.6) 28 (73.7) 39 (54.9) 16 (94.1)
Other specialist 7 (41.2) 19 (50.0) 49 (69.0) 7 (41.2)
Access to TSC clinic
Individuals had access
to clinic when required
13 (76.5) 29 (76.3) 43 (60.6) 16 (94.1)
Distance to TSC clinic from home
<50 km 10 (58.8) 14 (36.8) 18 (25.4) 4 (23.5)
>50 km 3 (17.6) 15 (39.5) 30 (42.3) 12 (70.6)
Individuals in contact with national TSC association
Yes 9 (52.9) 14 (36.8) 36 (50.7) 9 (52.9)
No 7 (41.2) 22 (57.9) 33 (46.5) 7 (41.2)
Data not available 1 (5.9) 2 (5.3) 2 (2.8) 1 (5.9)
*Participants may have provided more than one answer. Values are expressed as n (%).
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FIGURE 1 | Satisfaction with treatment aspects in (A) Self-reported children, (B) Self-reported adults, (C) Caregiver-reported children, and (D) Caregiver-reported
adults.
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TABLE 4 | Impact of TSC on education, employment and relationships.
Self-reported
individuals with TSC
Caregivers-reported
individuals with TSC
Adolescents
N = 17
Adults
N = 38
Children/
adolescents
N = 71
Adults
N = 17
Impact on education
Impact of TSC on
career/education of self or
caregivers (in case of
children)a
3 (17.6) 16 (42.1) 47 (66.2) 12 (70.6)
Career
progression/promotions
0 4 (25.0) 17 (36.2) 1 (8.3)
Choice of career 0 4 (25.0) 16 (34.0) 1 (8.3)
Loss of employment 2 (66.7) 5 (31.3) 10 (21.2) 1 (8.3)
Part-time work rather
than full time
0 5 (31.3) 25 (53.2) 1 (8.3)
Education level attained 1 (33.3) 6 (37.5) 3 (6.4) 10 (83.3)
Current employment status of self or caregivers (in case of
caregiver-reported children)
Employed (either full or
part-time)
11 (64.7) 20 (52.6) 47 (66.2) 3 (17.6)
Unable to work due to
condition
0 4 (10.5) 8 (11.3) 10 (58.8)
Unable to work but not
due to condition
0 3 (7.9) 8 (11.3) 1 (5.9)
Student 2 (11.8) 2 (5.3) 0 1 (5.9)
Homemaker 4 (23.5) 7 (18.4) 10 (14.1) 1 (5.9)
Impact of TSC on relationships of self or caregivers (in case of
caregiver-reported children)
Family relationships 3 (17.6) 8 (21.1) 29 (40.8) 4 (23.5)
Social relationships 2 (11.8) 14 (36.8) 36 (50.7) 11 (64.7)
Working colleague
relationships
0 4 (10.5) 17 (23.9) 1 (5.9)
Child is in mainstream
education
14 (82.4) NA 43 (60.6) NA
Child receives additional
support in class
6 (35.3) NA 31 (43.7) NA
Additional support
causes child additional
problems
2 (11.8) NA 13 (18.3) NA
a Individuals may have reported one or more ways of impact of career/education. Values
are expressed as n (%).
who were unable to complete the questionnaires
by themselves.
Of the 71 caregiver-reported children and adolescents, 20
(28.2%) needed help at home, provided mainly by unpaid
caregivers in 80% of cases (Table 2). Of the 17 caregiver-
reported adults, one (5.9%) was living alone, two (11.8%) with
a partner, and 13 (76.5%) with other family members. Eight
(47.1%) individuals needed help with daily activities. About
half of the caregiver-reported individuals (50.7% children and
adolescents, and 52.9% adults) were in contact with their local
TSC associations.
TSC was managed by TSC specialists in 39 (54.9%) caregiver-
reported children and adolescents, and 16 (94.1%) caregiver-
reported adults (Table 3). Twenty-three caregivers (32.4%)
reported that their children and adolescents did not have access to
TSC specialist clinics but most caregiver-reported adults (94.1%)
did. Most caregiver-reported children and adolescents (80.3%)
and caregiver-reported adults (94.1%) received genetic testing
for TSC, but genetic counselling was received only by 60.6% of
children and adolescents, and 58.8% of adults. None of the six
(35.3%) caregiver-reported adults who received private insurance
felt that they had to pay extra due to TSC and only one patient
(5.9%) reported that health or any kind of insurance was denied
due to TSC.
Caregivers have reported that TSC had affected the career
or education of their children and adolescents in different
ways. These include part-time work rather than full time
(53.2%), impact on career progression/promotions (36.2%),
choice of career (34.0%), loss of employment (21.2%), impact
on educational attainment (6.4%). Of the 17 caregiver-reported
adults, only three (17.6%) were employed while 10 (58.8%)
were unable to work due to TSC. Ten (83.3%) carer-reported
adults reported impact of educational attainment. Relationships
of caregivers had been impacted due to child’s TSC in 53.5% of
cases with impact on the family, social, and working colleague
relationships were reported in 29 (40.8%), 36 (50.7%), and 17
(23.9%) cases, respectively. Impact on the family, social and
working relationships by TSC condition have been noted in
76.5% of caregiver-reported adults.
Quality of Life (QoL) in TSC
EQ-5D Questionnaire
Overall, EQ-5D (or Q-5D proxy version 1) questionnaires were
completed for all 143 participants. Difficulty in mobility was
reported by 34 individuals (23.8%) and 32 (22.4%) experienced
difficulty in self-care. Twenty-six individuals (18.2%) were
unable to perform usual activities, fifty individuals (35%) had
moderate pain or discomfort and four individuals (2.8%) had
extreme pain or discomfort. Sixty-two individuals (43.4%)
reported moderate anxiety/depression, while six individuals
(4.2%) reported extreme anxiety/depression. Anxiety/depression
and pain/discomfort were reported in both self-reported as well
as caregiver-reported groups and present in both children and
adolescents, and adults (Figure 2). On the thermometer scale of
0–100 (100 being the best state of health imaginable and 0 as
worst state imaginable) the mean score was 70.6.
QOLIE-31-P Questionnaire
The QOLIE-31-P questionnaire was completed by 24 individuals.
The total score of the QOLIE-31-P questionnaire was 71.6
(standard deviation [SD]: ±16.7, Table 5). The mean (±SD)
score for different sub-scales were: energy (47.0 ± 27.6), mood
(53.4 ± 29.8), daily activities (67.0 ± 33.3), cognition (63.6 ±
37.5), medication effects (56.9 ± 31.5), seizure worry (49.8 ±
31.4), and overall quality of life (53.8± 29.1).
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FIGURE 2 | Summary of EQ-5D Questionnaire in (A) adults and (B) children.
QOLCE Questionnaire
The QOLCE questionnaire was completed by 70 caregivers.
The mean QOLCE score was 52.3 (SD: ±18.9, Table 5). The
mean (±SD) scores of different sub-scales were: QoL (51.5 ±
27.5), physical restrictions (44.6 ± 24.4), energy/fatigue (54.5
± 22.7), depression (70.7 ± 17.6), anxiety (58.8 ± 20.5),
control/helplessness (56.1 ± 20.1), self-esteem (63.9 ± 19.6),
attention/concentration (37.5 ± 28.7), memory (54.2 ± 23.8),
language (42.1 ± 28.7), other cognitive functions (31.7 ± 29.0),
social interactions (53.6 ± 21.7), social activities (63.8 ± 35.5),
stigma (66.1± 36.4), behaviour (50.5± 20.6), and general health
(48.5± 27.3). The highest score was reported for depression and
the lowest for other cognitive functions.
QOLIE-AD-48 Questionnaire
Eight adolescents aged 11–17 years with epilepsy completed
the questionnaire. The mean total QOLIE-AD-48 questionnaire
score was 74.2 (SD: ±13.9, Table 5). The score of the sub-scales
were epilepsy impact (82.7± 20.2), memory/concentration (74.1
± 22.3), physical functioning (83.1± 18.1), stigma (81.9± 22.2),
social support (69.5 ± 22.5), school behaviour (97.7 ± 3.2),
attitudes toward epilepsy (30.4 ± 7.6), and health perceptions
(61.5± 9.9).
DISCUSSION
This study aimed to evaluate BOI and QoL in children and
adolescents, and adults with TSC and their families. BOI focused
on social care needs, health (care) needs, and impact of TSC on
education, employment, and family life. Individuals’ QoL was
assessed by means of standardized measures of QoL. To our
knowledge, this study represented the most comprehensive and
multinational evaluation of BOI and QoL in TSC to date.
Four main findings were highlighted by this study. BOI
in families with TSC patients was high, as shown by their
experiences of insufficient assistance at home and from social
services. Individuals with TSC reported significant use of
healthcare services but considered the support from TSC
associations and patient organizations as inadequate. Also, the
impact of TSC on individuals’ education, employment, and
social and family life was profound. Regarding quality of life,
both children and adolescents, and adults reported moderate-
to-severe levels of pain or discomfort and anxiety or depression,
which was also indicated by their caregivers.
Individuals with TSC and their families have unmet needs
with respect to support from social workers who provide various
services, corresponding to previous findings (8). Most services
were not available, or not offered or performed properly. Possibly,
these professionals were insufficiently aware of the specific needs
of individuals with or lack the experience to provide appropriate
support. Another explanation for this unmet need might be
difficulty in reaching out to families of individuals with TSC by
social workers due to practical reasons, or families of individuals
with TSC had personal barriers to seek help. Clearly, our findings
underline the urgent need for increased awareness among social
services about the importance of early and systematic follow-up
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TABLE 5 | Summary of QOLIE-31-P, QOLCE and QOLIE-AD-48 questionnaire
scores.
n Mean SD Median Range
QOLIE-31-P
Energy 24 47.0 27.6 45.0 2.5–90
Mood 24 53.4 29.8 63.5 3.6–92
Daily activities 24 67.0 33.3 73.1 3.8–100
Cognition 24 63.6 37.5 71.1 0.3–100
Medication effects 24 56.9 31.5 57.5 1.3–100
Seizure worry 24 49.8 31.4 45.8 0.4–100
Overall QoL 24 53.8 29.1 58.1 3.3–95
Final Score 24 71.6 16.7 75.8 27.3–93.4
QOLCE
QoL 67 51.5 27.5 50.0 0–100
Physical restrictions 69 44.6 24.4 45.8 0–100
Energy/fatigue 67 54.5 22.7 62.5 0–100
Depression 68 70.7 17.6 75.0 8.3–100
Anxiety 68 58.8 20.5 50.0 25–100
Control/helplessness 64 56.1 20.1 50.0 18.8–100
Self-esteem 65 63.9 19.6 70.0 15–95
Attention/concentration 66 37.5 28.7 32.3 0–100
Memory 58 54.2 23.8 56.3 0–100
Language 60 42.1 28.7 44.4 0–100
Other cognitive functions 64 31.7 29.0 25.0 0–100
Social interactions 56 53.6 21.7 60.0 0–100
Social activities 67 63.8 35.5 66.7 0–100
Stigma 56 66.1 36.4 75.0 0–100
Behaviour 69 50.5 20.6 48.4 0–93.8
General health 68 48.5 27.3 50 0–100
Final score 70 52.3 18.9 51.5 12.2–91.7
QOLIE-AD-48
Epilepsy impact 8 82.7 20.2 91.7 39.6–95.8
Memory/concentration 8 74.1 22.3 82.5 45–100
Physical functioning 8 83.1 18.1 87.5 55–100
Stigma 8 81.9 22.2 83.3 33.3–100
Social support 8 69.5 22.5 59.4 43.8–100
School behaviour 8 97.7 3.2 100.0 93.8–100
Attitudes toward epilepsy 7 30.4 7.6 31.3 18.8–37.5
Health perceptions 8 61.5 9.9 58.3 50.0–75
Final score 7 74.2 13.9 81.2 46.1–85.7
of individuals with TSC and their environment (21). When
such needs remain unrecognised, family members feel urged
to take on various responsibilities and failed to introduce
further professional care in a timely manner, preventing optimal
guidance with attention to individual goals or preferences.
Individuals with TSC showed various clinical manifestations
for which they visited health specialists. Throughout their
lives, they made significant use of healthcare services as a
result of the regular multidisciplinary medical care indicated
for the management of TSC (22). However, the present study
showed that high healthcare utilization and followed-up by a
TSC specialist or clinic were unrelated to involvement of TSC
associations and patient organizations in the individual’s care
trajectory. Reasons could be that patients were not familiar
with them, not convinced of their significance for their own
situation or experience sufficient support from their own private
network. It was also plausible that these societal partners failed
to reach families with TSC in the right way or did not meet their
expectations regarding types of support.
The observed lack of appropriate care services was also
reflected in differences between individuals in terms of health
insurance, and genetic testing, and counselling. These findings
indicate a need for revision and standardization of insurance
policies for people with TSC or chronic conditions in general,
as well as clinical care characterized by a personalized and
transparent approach. Despite this imbalance between care need
and care provision, individuals in this study reported satisfaction
with how their disease was treated and monitored. Furthermore,
the transition from paediatric to adult TSC care was an important
area of concern (23). Although this phase is generally considered
challenging or difficult (24), our results showed a smooth process
in almost half of the cases. Transition-enhancing practices such as
use of an individual action plan, implementation of a transition
protocol and setting up a mixed paediatric-adult team with a
transition coordinator might be useful in TSC care (25, 26).
TSC had a strong influence on the education and professional
career of affected individuals. Especially in adults, their level of
education, choice of career, career progression and promotion,
and employment rate were impacted by the disease. Apart from
the presence of TSC, other influences, directly or indirectly,
related to the illness should be taken into account. Having
few professional expectations for the future, being confronted
with negative attitudes of colleagues and lacking arrangements
to improve working conditions, might all further reduce the
patient’s opportunities at work (27, 28). The impact of TSC on
education was relatively minor in the group of self-reporting
adolescents, a finding that is likely biased by their assumed
milder phenotype since they were able to fill-out the BOI and
QOL questionnaires independently. Previous research showed
a higher degree of absenteeism, impaired performance, and
lower productivity at school in paediatric patients (28). It seems
therefore advisable to guide young patients on study choice and
keep track of adults’ working life, while listening to expressed
questions, concerns, and problems.
TSC has significant effects on the social well-being and family
life of both young and adult individuals with TSC. The patients’
high dependence on their environment can lead to feelings of
disorientation, loneliness, and clinically significant stress levels in
patients, but also in family members (10, 17). Our data show the
marked effect of TSC on the income, career, and psychological
well-being of the individual’s family. Therefore, it is essential
to identify and approach the sources of such familial distress,
which vary according to the patient’s personal characteristics,
health status, and living environment. Problems in children and
adults with TSC such as severe epilepsy and other persistent
health problems, neuropsychiatric disorders (TAND) and a lack
of support from the family’s network can put a heavy burden
on the family of individuals with TSC (2, 29, 30). As a result,
the family may become isolated as friendships and professional
relationships receive less attention (16). However, it has been
shown that external support might help building the family’s
resources, as they can cope better with the multifaceted problems
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of TSC and regularly shift their attention from the disease to
pleasant events and moments in life (10).
With regard to QoL, moderate to severe levels of pain
or discomfort and anxiety or depression were reported
by individuals with TSC of all ages as well as by their
caregivers. In order to achieve a comprehensive view of health-
related QoL in individuals with TSC, research suggested to
investigate other indicators such as fatigue, emotional stress,
and participation (31). In particular, participation is important,
as this multidimensional concept captures how the patient’s
health determines his or her participation in daily life, taking
into account functional and intellectual disabilities. Assessing
the individual’s participation rate in terms of education, social
activities, and leisure time is required for the development of
interventions, which enable a long life with a good QoL (32).
In future studies on BOI and QoL, standardized instruments to
measure participation such as questionnaires for patients and
carers could be used (33, 34).
When interpreting the results of this study, certain limitations
need to be taken into account. Not all patients completed all
questionnaires in the study, and only a small subsample of
patients from the TOSCA registry enrolled in the present study.
Although the information was collected from both individuals
who were able to self-report as well as from caregivers of
individuals who were unable to self-report, the overall disease
severity of the cohort is likely to be milder compared to that
of the global TOSCA registry cohort. Only 46.85% of patients
in the current study was reported to have epilepsy in contrast
to 83.5% in the overall TOSCA cohort (35). Since epilepsy is
known to have a major impact on QoL (36), the burden of illness
reported here might reflect the impact at the milder end of the
spectrum. Furthermore, these subjects were all recruited from
clinicians specialized in TSC care. Therefore, the level of care and
satisfaction in the general TSC population is likely to be lower.
Although no data on intellectual ability were collected, 65%
of children were following mainstream education. Although
school systems differ across countries and attending mainstream
education does not imply that children have normal intellectual
ability, it seems likely that this reflects again a potential bias
towards the milder end of the spectrum. The lack of a personal
perspective is another limitation of the study. The questionnaire
used to measure BOI contained questions that were developed
together with families, which ensures a large patient-oriented
input. Although no qualitative research was conducted, a short
analysis of the questionnaire’s open data fields did confirm the
quantified BOI (data not shown).
CONCLUSION
Our study confirms the impact of TSC on education, career
and social life of patients, and their families. This disease-
specific impact is also reflected in patients’ quality of life,
including moderate-to-high levels of pain or discomfort and
anxiety or depression. Unfortunately, despite families’ frequent
use of healthcare services, provision of well-organized TSC care
is not evident as shown by their experiences of insufficient
social support and discontinuous pediatric to adult care
trajectories. These difficulties further increase the impact on the
different life domains of families living with TSC, who would
benefit from better coordinated educational, psychosocial, and
medical support.
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